Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

Next Previous
Trial Profile

PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PROMOTE

    • Most Recent Events

    • 04 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 05 Jun 2018 Results of a transcriptome analysis assessing predictor of response to abiraterone acetate/prednisone (n=58), presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 31 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top